Overview
MBX market data
Price History
MBX price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$2.38 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.55 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $9.63 – $66.55 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $2.9K · P/B 3.84.
Company news
ManpowerGroup Posts Upbeat Q2 Earnings, Joins Docebo, Zentalis Pharmaceuticals And Other Big Stocks Moving Higher On FridayBenzinga · Jul 17, 2026, 2:09 PM
MBX Biosciences shares are trading lower. The company announced the appointment of Steve Hoerter as Chairman and CEO.Benzinga · Jul 14, 2026, 12:59 PM
8-K filing — MBX Biosciences, Inc. (MBX)SEC EDGAR · Jul 13, 2026, 8:46 PM
MBX Biosciences Appoints Steve Hoerter As Chairman And CEO, Succeeding Kent Hawryluk, With John Smither Named Interim CFO, Effective ImmediatelyBenzinga · Jul 13, 2026, 8:19 PM
MBX Biosciences Highlights Sustained Calcium Control In Rare DiseaseBenzinga · Jun 12, 2026, 2:45 PM
Lennar Reports Mixed Q2 Results, Joins Adobe And Other Big Stocks Moving Lower In Friday's Pre-Market SessionBenzinga · Jun 12, 2026, 12:05 PM
MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic HypoparathyroidismGlobenewswire Inc · Jun 12, 2026, 11:15 AM
MBX Biosciences Announces Full Results From 12-Week Avail Phase 2 Trial And New 1-Yr Data From Ongoing OLE Study Of Once-Weekly Canvuparatide In Adult Patients With Chronic HypoparathyroidismBenzinga · Jun 12, 2026, 11:05 AM
Earnings Scheduled For May 14, 2026Benzinga · May 14, 2026, 11:11 AM
AstraZeneca's Rare Disease Drug Shows Reduced Dependence On Calcium SupplementsBenzinga · May 12, 2026, 3:15 PM